News

Anxiety and Depression Linked to RRMS Relapse Risk, Study Finds

Comorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial analysis has found.  Anxiety and abnormal blood lipids (fats) also increased the risk of any RRMS disease activity.  Based on those findings, researchers…

Study of Temelimab in MS Progression Without Relapse Enrolls 1st Patient

GeNeuro announced that a first multiple sclerosis (MS) patient has enrolled in its Phase 2 trial assessing the safety and effectiveness of temelimab in people whose disease is progressing in the absence of relapses. This trial, taking place at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, had been postponed to reduce…

Tecfidera Safe and Effective Over Years of Use, RRMS Study Finds

Tecfidera (dimethyl fumarate) is safe and effective as a long-term treatment for relapsing-remitting multiple sclerosis (RRMS), a study of clinical trial data covering up to 11 years of treatment suggests. The study, “Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis:…

NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS

The National Institute for Health and Care Excellence (NICE) is recommending against Mayzent (siponimod) as a treatment for active secondary progressive multiple sclerosis (SPMS) in the U.K., because its cost-effectiveness relative to an existing treatment for these patients is not known. NICE’s draft guidance for Mayzent is open…

More Research Needed Into How Exercise, Rehab Aid Cognition in MS

Cognitive problems are common in people with multiple sclerosis (MS) but inadequately addressed by disease-modifying therapies, while cognitive rehabilitation and exercise training programs can be effective, a review study reported.  Research studies of exercise programs need to include larger groups of patients with demonstrated cognitive difficulties, however, and more pharmacological…

CMSC Meeting Focuses on Challenges, Solutions to Quality of Life Issues

Nearly 3,000 multiple sclerosis (MS) healthcare providers and researchers  convened recently to share their findings regarding the latest developments in the diagnosis and treatment of MS. However, unlike past meetings, this year’s 34th Annual Meeting of the Consortium of MS Centers (CMSC) took place online. Virtual presentations covered the…

Obesity Linked to Faster Optic Nerve Atrophy, Study Finds

Multiple sclerosis (MS) patients who are obese experience faster degeneration in optic nerve tissue than do those of normal weight, an observational study found. Since optic nerve degeneration correlates with greater nerve loss in the brain, measuring changes in this tissue may be a feasible way to determine…

$7.2M NIH Grant Supports Study of MS Diagnostic Biomarker

The National Institutes of Health (NIH) awarded a $7.2 million grant to a team led by Cleveland Clinic researchers that will study whether a new biomarker might more accurately diagnose multiple sclerosis (MS). Grant money will support a study in 400 adults suspected of having MS to determine if the…